Zobrazeno 1 - 10
of 10
pro vyhledávání: '"556"'
Autor:
Kentaro Kishi, Yasuo Urata, Masaki Mori, Kenta Furukawa, Toshimitsu Irei, Masaki Wakasugi, Masashi Inoue, Shinya Yamashita, Yuichiro Doki, Masahiro Tanemura, Hiroaki Nagano, Nobuyoshi Hatanaka, Hiroki Akamatsu
Publikováno v:
Cancer Research. 75:556-556
Circulating tumor cells (CTCs) are thought to be “metastatic intermediates”. Recently, we reported encouraging survival rates following neoadjuvant therapy using gemcitabine (Gem) and S-1 concurrently with radiotherapy (NACRT) in patients (pts) w
Publikováno v:
Cancer Research. 71:556-556
Sulfatase 2 (Sulf2) is an extracellular enzyme which catalyzes the removal of 6-O-sulfate groups on glucosamine from subregions of the glycosaminoglycan heparin sulfate. Sulf2 action alters the binding of protein ligand growth factors such as VEGF, F
Publikováno v:
Cancer Research. 70:P2-06
Purpose: A strong prognostic impact of urokinase type plasminogen activator (uPA) and its inhibitor plasminogen activator inhibitor type 1 (PAI-1) as individual factors is well established, with a level of evidence I according to the ASCO recommendat
Publikováno v:
Cancer Research. 81:PO-051
Tumor Treating Fields (TTFields) are a non-invasive, loco-regional antimitotic treatment modality, approved for the treatment of glioblastoma and malignant pleural mesothelioma. TTFields at a specific frequency (150-200 kHz) are delivered via arrays
Autor:
Ryan J. Hartmaier, Martin Johnson, Helen Tomkinson, Ganesh Mugundu, James Dunyak, Aleksandra Markovets, Juliann Chmielecki, Karthick Vishwanathan, Carl Barrett, Philip Overend
Publikováno v:
Cancer Research. 80:CT024-CT024
Circulating tumor DNA is released into the bloodstream from tumors and can reflect both intra-tumor heterogeneity and clonal evolution.1 As ctDNA levels are thought to reflect tumor burden, a decrease in ctDNA while on therapy may suggest treatment e
Autor:
Xiaojia Wang, Zefei Jiang, Guyin Lou, Biyun Wang, Zhongsheng Tong, Binghe Xu, Jianfeng Luo, Y. Pan, Zhimin Shao, Yongmei Yin, Li Cai, Changping Wu, Donggeng Liu, Jifeng Feng, Y. Teng, Zhonghua Wang, Joseph Ragaz, Jian Zhang, Xichun Hu, Jiong Wu
Publikováno v:
Cancer Research. 75:P3-10
Background: There is still no standard chemotherapy for patients with metastatic triple-negative breast cancer (mTNBC). Our previous phase II pilot trial with first-line gemcitabine and cisplatin combination (GP) in patients with mTNBC (clinicaltrial
Autor:
Christian U. Blank, Michal Lotem, Clemens Krepler, Teresa M. Petrella, Matteo S. Carlino, Caroline Robert, Georgina V. Long, Paul Lorigan, Antoni Ribas, James Larkin, Omid Hamid, Laurent Mortier, Jean-Jacques Grob, James R. Anderson, Catriona M. McNeil, Scott J. Diede, Bart Neyns, Ana Arance, Jacob Schachter, Adil Daud
Publikováno v:
Cancer Research. 79:CT188-CT188
Introduction: Pembro significantly improved OS vs ipi in advanced melanoma in the KEYNOTE-006 study (NCT01866319). We present outcomes from the 5-year follow-up of this study−the longest to date in a randomized phase 3 trial of pembro in advanced c
Publikováno v:
Cancer Research. 79:CT176-CT176
Background: Tumor Treating Fields (TTFields) are a non-invasive, regional antimitotic treatment modality, which has been approved for the treatment of patients with glioblastoma by the FDA. TTFields predominantly act by disrupting the formation of th
Autor:
Giampaolo Bianchini, L. Gianni, William Fraser Symmans, Milvia Zambetti, Takayuki Iwamoto, L Pusztai, Catherine M. Kelly, G Del Conte, Libero Santarpia, Angelica Fasolo
Publikováno v:
Cancer Research. 71:S1-7
Background Used upfront or after 2 to 3 years (yrs) of tamoxifen (TAM) or as extended treatment after 5 yrs of TAM, aromatase inhibitors (AIs) are associated with less recurrences than with 5 yrs of TAM. However, up front AIs were not superior to TAM
Publikováno v:
Cancer Research. 78:CT157-CT157
Tumor Treating Fields (TTFields) are a non-invasive, regional antimitotic treatment modality, which has been approved for the treatment of patients with glioblastoma by the FDA. TTFields predominantly act by disrupting the formation of the mitotic sp